Literature DB >> 14714187

Long-term results after surgical extraction of subfoveal choroidal neovascular membranes with and without haemorrhage in age-related macular degeneration.

Ameli Gabel-Pfisterer1, Jessica Laue, Heinrich Heimann, Claudia Jandeck, Ulrich Kellner, Norbert Bornfeld, Michael H Foerster.   

Abstract

BACKGROUND: Surgical extraction has been suggested as a treatment of choroidal neovascular membranes. We demonstrate the long-term results of our patients regarding complications, risk of recurrence and development of visual acuity.
METHODS: We have retrospectively evaluated the charts and re-examined the patients who underwent surgical extraction of choroidal neovascular membranes (CNV) because of age-related macular degeneration (AMD) between March 1994 and December 2000 in the Department of Ophthalmology of the Benjamin Franklin Clinic, Berlin. Fifty-two eyes of 49 patients with a minimum follow-up of 12 months after pars plana vitrectomy with CNV extraction and SF6-endotamponade were included. Initially, in 15% of all eyes the lesions were obscured by intravitreal haemorrhage. All visible lesions were located subfoveally. In 40% of all eyes the lesion was predominantly classic; 21% of the lesions were predominantly occult and 23% of the lesions were comprised of more than 50% haemorrhage. The maximum follow-up was 80 months, the mean 46 months.
RESULTS: The median initial visual acuity was 0.08 (range: hand movements to 0.4) and the median final visual acuity was not significantly different at 0.067 (range: non lux to 0.4). A loss of less than three lines of visual acuity occurred in 65.4% of our patients. During follow-up, 25% of eyes developed a rhegmatogenous retinal detachment and 19.2% of all eyes suffered from recurrence of CNV. At the end of the follow-up, three eyes (5.8%) suffered from non-treated retinal detachment and three eyes (5.8%) had recurrent CNV lesions. All eyes showed a retinal pigment epithelium defect at the site of former CNV.
CONCLUSION: A stabilisation of visual acuity in individual patients with CNV because of AMD can be achieved by surgical extraction, yet the defect of the RPE and the risk of complications limit the benefit. We consider the surgical extraction of CNV from AMD in patients with low initial visual acuity who are not amenable to PDT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14714187     DOI: 10.1007/s00417-003-0825-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  20 in total

1.  Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration.

Authors:  P F Lopez; H E Grossniklaus; H M Lambert; T M Aaberg; A Capone; P Sternberg; N L'Hernault
Journal:  Am J Ophthalmol       Date:  1991-12-15       Impact factor: 5.258

2.  Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration.

Authors:  E de Juan; R Machemer
Journal:  Am J Ophthalmol       Date:  1988-01-15       Impact factor: 5.258

3.  Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration.

Authors:  C Eckardt; U Eckardt; H G Conrad
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-04       Impact factor: 3.117

4.  The Swedish national survey of surgical excision for submacular choroidal neovascularization (CNV).

Authors:  L Berglin; P Algvere; G Olivestedt; S Crafoord; S Stenkula; L J Hansson; Z Tomic; A Kvanta; S Seregard
Journal:  Acta Ophthalmol Scand       Date:  2001-12

5.  Clinical experience with the surgical removal of subfoveal neovascular membranes. Short-term postoperative results.

Authors:  A S Berger; H J Kaplan
Journal:  Ophthalmology       Date:  1992-06       Impact factor: 12.079

6.  [Surgical removal of submacular neovascularization membranes].

Authors:  C Eckardt
Journal:  Ophthalmologe       Date:  1996-12       Impact factor: 1.059

7.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

8.  Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration.

Authors:  Sabine Aisenbrey; Bart A Lafaut; Peter Szurman; Salvatore Grisanti; Christoph Lüke; Ralf Krott; Gabriele Thumann; Julia Fricke; Antje Neugebauer; Ralf-Dieter Hilgers; Peter Esser; Peter Walter; Karl Ulrich Bartz-Schmidt
Journal:  Arch Ophthalmol       Date:  2002-04

9.  Surgical extraction of subfoveal choroidal new vessels and submacular haemorrhage in age-related macular degeneration: results of a prospective study.

Authors:  A Scheider; O Gündisch; A Kampik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-01       Impact factor: 3.117

10.  Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration.

Authors:  L D Ormerod; J E Puklin; R N Frank
Journal:  Ophthalmology       Date:  1994-07       Impact factor: 12.079

View more
  3 in total

1.  Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration.

Authors:  Michael J Potter; Shelagh M Szabo
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

2.  [Photodynamic therapy with verteporfin for recurrent choroidal neovascularisation (CNV) following prior argon laser coagulation].

Authors:  A Gabel-Pfisterer; A Wehner; H Heimann; M H Foerster; J Wachtlin
Journal:  Ophthalmologe       Date:  2005-06       Impact factor: 1.059

3.  The end of submacular surgery for age-related macular degeneration? A meta-analysis.

Authors:  Christiane I Falkner; Harald Leitich; Florian Frommlet; Peter Bauer; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-05-04       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.